IDH mutations, Figure 1, are associated with a significantly longer survival time compared with IDH wild-type tumors in patients age ≥60 years with anaplastic astrocytoma and glioblastoma; therefore, the absence of this mutation correlates with a poor prognosis [34]. The gene discussed is IDH1; the disease is glioblastoma.